---
title: "TJPC: Received the approval notice for the listing application of chemical raw materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255158286.md"
description: "TJPC announced that it recently received the \"Approval Notice for the Market Application of Chemical Raw Materials\" for Difluprednate issued by the National Medical Products Administration. Difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. The main dosage form currently available on the market is eye drops, primarily used to treat inflammation and pain related to eye surgery. According to the IQVIA database, the global sales of Difluprednate formulations are projected to be USD 49 million and USD 41 million in 2023 and 2024, respectively"
datetime: "2025-08-29T09:01:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255158286.md)
  - [en](https://longbridge.com/en/news/255158286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255158286.md)
---

# TJPC: Received the approval notice for the listing application of chemical raw materials

TJPC announced that it recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for difluprednate issued by the National Medical Products Administration. Difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. The main formulation available in the market is eye drops, primarily used for treating inflammation and pain related to eye surgeries. According to the IQVIA database, the global sales of difluprednate formulations are projected to be USD 49 million and USD 41 million in 2023 and 2024, respectively

### Related Stocks

- [600488.CN](https://longbridge.com/en/quote/600488.CN.md)

## Related News & Research

- [Flight 13 of Starship was (mostly) a triumph for SpaceX](https://longbridge.com/en/news/294608682.md)
- [ASPO: Strong Q2 profit growth and a board-approved demerger set the stage for focused future growth](https://longbridge.com/en/news/294689293.md)
- [Elite Pharma launches generic Requip XL ropinirole extended-release tablets in US](https://longbridge.com/en/news/294812400.md)
- [Toralgen Demonstrates Oral Delivery Across Multiple Diabesity Peptide Classes, Advancing the Potential of Oral Biologics](https://longbridge.com/en/news/294857699.md)
- [12:30 ETNew Platform, New Conversation: Oversee Unveils AgentSee AI Chat Feature and Platform Redesign](https://longbridge.com/en/news/294718533.md)